Business
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatmentRolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first hal
About this update from Intellia Therapeutics, Inc.
[{"type":"image","alt":"Intellia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Intellia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E8KNdwU6yVQf4O84cdCx6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed ","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatment","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"Rolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approved","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Intellia to host webcast today at 8:00 a.m. ET","length":46,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":572,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE). HAE is a rare genetic condition in which patients experience recurrent and potentially life-threatening swelling (angioedema) attacks in various parts of their body, including the face, upper airway, abdomen and extremities due to an overproduction of bradykinin. Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels.","leng...